Related Experiment Video
Updated: Jul 24, 2025
Laminectomy and Spinal Cord Window Implantation in the Mouse
Published on: October 23, 2019
Downregulated CAV-1 in mouse spinal cord may alleviate bone cancer pain by inhibiting the ERK/CREB pathway
Jianyun Ge1, Jie Song2, Bo Sun1
1Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Background:
This study aimed to assess the potential function of Caveolin-1 (CAV-1) in mice with bone cancer pain.
Method:
Using a mice bone cancer pain model we explored the contribution of CAV-1 expression to bone cancer pain on the 14th day after surgery, mice in the tumor group were randomized and treated with increasing doses of the CAV-1 inhibitor, methyl-beta-cyclodextrin. Pain was assessed by monitoring the number of spontaneous flinches (NSF) and paw withdrawal mechanical threshold (PMWT)mechanical withdrawal threshold (MWT). The localization and expression of CAV-1 in mouse neurons was also determined. Additionally, the protein levels of CAV-1, extracellular signal regulated kinase (ERK) 1/2, cAMP response element-binding protein (CREB) were monitored in mouse spinal cord tissues by western blotting.
Results:
CAV-1 was remarkably upregulated in the spinal cord of the tumor group on the 4th day after surgery, then downregulated on day 10, and upregulated again at day 14. Such CAV-1 levels were maintained until day 28. In the tumor group, the expression of p-ERK1/2 and p-CERB were upregulated at day 14 after surgery. Intrathecal injection of methyl-beta-cyclodextrin (MCD) downregulated p-ERK1/2 and p-CERB expression which correlated with alleviation of pain.
Conclusion:
Inhibition of CAV-1 in the spinal cord alleviates bone cancer pain in mice which correlates with inhibition of the ERK/CREB pathway.
Insights
Inhibiting Caveolin-1 (CAV-1) in mouse spinal cords reduces bone cancer pain. This effect is linked to suppressing the ERK/CREB signaling pathway, offering a potential therapeutic target for pain management.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Bone cancer pain is a significant clinical challenge.
- Caveolin-1 (CAV-1) is implicated in various cellular processes, but its role in bone cancer pain is not fully understood.
Purpose of the Study:
- To investigate the functional role of Caveolin-1 (CAV-1) in a mouse model of bone cancer pain.
- To explore the therapeutic potential of targeting CAV-1 for pain relief.
Main Methods:
- A mouse model of bone cancer pain was established.
- Mice were treated with methyl-beta-cyclodextrin (MCD), a CAV-1 inhibitor.
- Pain was assessed using behavioral tests (spontaneous flinches, mechanical withdrawal threshold).
- CAV-1 expression and signaling pathway components (ERK, CREB) were analyzed in spinal cord tissue via western blotting.
Main Results:
- CAV-1 expression in the spinal cord showed dynamic changes following tumor induction, with significant upregulation at specific time points.
- Inhibition of CAV-1 with MCD led to a significant reduction in pain behaviors.
- MCD treatment decreased the expression of phosphorylated ERK (p-ERK) and phosphorylated CREB (p-CREB) in the spinal cord.
Conclusions:
- Inhibition of spinal CAV-1 effectively alleviates bone cancer pain in mice.
- The analgesic effect of CAV-1 inhibition is associated with the suppression of the ERK/CREB signaling pathway.
- Targeting CAV-1 presents a promising strategy for managing bone cancer pain.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...